Dachaigh › Luchd-obrach › Kiniksa Pharmaceuticals Corp.
Kiniksa Pharmaceuticals Corp.: Tuarastalan H-1B agus taic bhìosa
Chuir Kiniksa Pharmaceuticals Corp. 7 iarrtasan cumha-obrach a-steach airson bhìosaichean H-1B agus bhìosaichean co-cheangailte ann am bliadhnaichean ionmhais 2023–2026; le teisteanas: 7. Tuarastal meadhanach a chaidh a thabhann: $140,000.
A bheil Kiniksa Pharmaceuticals Corp. a’ toirt taic do bhìosaichean H-1B?
Chuir Kiniksa Pharmaceuticals Corp. 7 iarrtasan cumha-obrach a-steach ann am bliadhnaichean ionmhais 2023–2026, an tè as ùire air a chur a-steach air 9 Cèit 2025. Is e LCA a’ chiad cheum ann an iarrtas H-1B, mar sin tha an neach-fastaidh air taic a thoirt do luchd-obrach H-1B no air ullachadh airson sin a dhèanamh; cha gharantaich e taic airson dreuchd shònraichte sam bith. Thoir sùil air liostaichean obrach an neach-fastaidh fhèin.
Tuarastalan a rèir tiotal obrach
| Tiotal dreuchd | LCAs | Tuarastal meadhanach |
|---|---|---|
| Director, Biostatistics | 1 | $137,966 |
| Associate Scientist, Analytical Sciences & Quality Testing | 1 | $98,000 |
| Director, Medical Affairs – Real-World Evidence & Epidemiolo | 1 | $220,000 |
| Manager, Quality Control | 1 | $140,000 |
| Scientist, Analytical Science & Quality Testing | 1 | $109,802 |
| Senior Director, Global Medical Safety | 1 | $290,000 |
| Associate Director, Clinical Quality Assurance | 1 | $189,930 |
Iarrtasan a rèir bliadhna ionmhais
| Bliadhna mhaoine | LCAs | Tuarastal meadhanach |
|---|---|---|
| FY2023 | 3 | $137,966 |
| FY2024 | 2 | $124,901 |
| FY2025 | 2 | $239,965 |
Ìrean tuarastail làithreach
Suidhichidh Roinn an Obrach ceithir ìrean tuarastail làithreach airson gach dreuchd agus sgìre, bho Ìre I (inntrigeadh) gu Ìre IV (gu tur comasach). Taghaidh an neach-fastaidh an ìre a fhreagras ri riatanasan na h-obrach.
Far a bheil na h-obraichean
Dreuchdan
- Statisticians1
- Biochemists and Biophysicists1
- Epidemiologists1
- Industrial Engineers1
- Chemists1
- Regulatory Affairs Managers1
- Regulatory Affairs Specialists1
Iarrtasan as ùire
| Tiotal dreuchd | Tuarastal bunasach | Àite | Air a chur a-steach | Ceann-latha tòiseachaidh | Inbhe |
|---|---|---|---|---|---|
| Associate Director, Clinical Quality Assurance | $189,930 Ìre IV | Lexington, MA | 9 Cèit 2025 | 1 Dàmh 2025 | Dearbhaichte |
| Senior Director, Global Medical Safety | $290,000 Ìre IV | Lexington, MA | 13 Màrt 2025 | 7 Gibl 2025 | Dearbhaichte |
| Scientist, Analytical Science & Quality Testing | $109,802 | Lexington, MA | 29 Gearr 2024 | 28 Lùna 2024 | Dearbhaichte |
| Manager, Quality Control | $140,000 Ìre IV | Lexington, MA | 7 Samh 2023 | 13 Samh 2023 | Dearbhaichte |
| Director, Medical Affairs – Real-World Evidence & Epidemiolo | $220,000 Ìre IV | Lexington, MA | 30 Ògmh 2023 | 24 Iuch 2023 | Dearbhaichte |
| Associate Scientist, Analytical Sciences & Quality Testing | $98,000 Ìre I | Lexington, MA | 11 Gibl 2023 | 1 Dàmh 2023 | Dearbhaichte |
| Director, Biostatistics | $137,966–$230,000 Ìre IV | Lexington, MA | 27 Gearr 2023 | 13 Màrt 2023 | Dearbhaichte |
Is e na tuarastalan an ìre as ìsle den tuarastal a chaidh a thabhann air gach iarrtas, air an tionndadh gu suim bhliadhnail; cleachdaidh na staitistigean iarrtasan làn-aimsire le teisteanas a-mhàin. Chan eil LCA na aontachadh bhìosa agus faodaidh aon LCA còmhdach a dhèanamh air iomadh dreuchd. Stòr: Roinn an Obrach na SA, Dàta Foillseachaidh OFLC LCA, bliadhnaichean ionmhais 2023–2026 (co-dhùnadh as ùire 30 Ògmh 2026).